Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 39Ovarian Neoplasms 32Triple Negative Breast Neoplasms 19Prostatic Neoplasms 17Fallopian Tube Neoplasms 16Neoplasm Metastasis 14Pancreatic Neoplasms 9Neoplasms 9Endometrial Neoplasms 9Carcinoma, Non-Small-Cell Lung 7Small Cell Lung Carcinoma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Glioma 6Stomach Neoplasms 5Sarcoma 5Lung Neoplasms 5Glioblastoma 5Squamous Cell Carcinoma of Head and Neck 4Metastatic Castration-resistant Prostate Cancer 4Carcinoma, Ovarian Epithelial 4Solid Tumors 3Recurrence 3Osteosarcoma 3Neuroendocrine Tumors 3Lymphoma, Non-Hodgkin 3Cholangiocarcinoma 3Urinary Bladder Neoplasms 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Prostatic Neoplasms, Castration-Resistant 2

Interventions

tetracarboxyphenylporphine 1testosterone enanthate 1testosterone 17 beta-cypionate 1olaparib 1Testosterone Propionate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Castration-Resistant Prostate Carcinoma × olaparib × 1 year × Clear all
NCT03516812 2025-09-29

Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

University of Washington

Phase 2 Completed
36 enrolled 14 charts
Genitourinary

Castration-Resistant Prostate Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡